Humana (NYSE:HUM) Issues FY 2025 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 16.250-16.250 for the period, compared to the consensus estimate of 16.910. The company issued revenue guidance of -.

Humana Price Performance

HUM stock opened at $266.91 on Tuesday. The business’s 50-day moving average is $274.21 and its two-hundred day moving average is $297.52. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $32.14 billion, a P/E ratio of 23.64, a P/E/G ratio of 2.11 and a beta of 0.56. Humana has a 1 year low of $213.31 and a 1 year high of $406.46.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts anticipate that Humana will post 16.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

HUM has been the subject of several analyst reports. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Barclays increased their price target on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 22nd. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Morgan Stanley increased their target price on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Finally, TD Cowen boosted their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $297.68.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.